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Neuroblastoma (NB) is the most common extra-cranial solid tumor of childhood and
arises from developing sympathetic nervous system. Most primary tumors localize in the
abdomen, the adrenal gland, or lumbar sympathetic ganglia. Amplification in tumor cells
of MYCN, the major oncogenic driver, patients’ age over 18 months, and the presence at
diagnosis of a metastatic disease (stage IV, M) identify NB at high risk of treatment failure.
Conventional therapies did not significantly improve the overall survival of these patients.
Moreover, the limited landscape of somatic mutations detected in NB is hampering the
development of novel pharmacological approaches. Major efforts aim to identify novel NB-
associated surface molecules that activate immune responses and/or direct drugs to tumor
cells and tumor-associated vessels. PVR (Poliovirus Receptor) and B7-H3 are promising tar-
gets, since they are expressed by most high-risk NB, are upregulated in tumor vasculature
and are essential for tumor survival/invasiveness. PVR is a ligand of DNAM-1 activating
receptor that triggers the cytolytic activity of natural killer (NK) cells against NB. In animal
models, targeting of PVR with an attenuated oncolytic poliovirus induced tumor regression
and elimination. Also B7-H3 was successfully targeted in preclinical studies and is now
being tested in phase I/II clinical trials. B7-H3 down-regulates NK cytotoxicity, providing
NB with a mechanism of escape from immune response. The immunosuppressive poten-
tial of NB can be enhanced by the release of soluble factors that impair NK cell function
and/or recruitment. Among these, TGF-β1 modulates the cytotoxicity receptors and the
chemokine receptor repertoire of NK cells. Here, we summarize the current knowledge on
the main cell surface molecules and soluble mediators that modulate the function of NK
cells in NB, considering the pros and cons that must be taken into account in the design
of novel NK cell-based immunotherapeutic approaches.
Keywords: neuroblastoma, natural killer cells, PVR, B7-H3,TGF-beta, tumor escapemechanisms, immunotherapeu-
tic approaches, chemokine receptors
NEUROBLASTOMA, WHERE ARE WE?
Neuroblastoma is a very heterogeneous disease (1) that includes
rare familial (<2%) and sporadic forms. It presents as a locore-
gional (Stage 1, 2, and 3 or L1, L1/L2, and L2) or progressing
metastatic disease involving bone, skin, liver, brain, and bone
marrow (BM), the latter being frequently refractory to standard
therapy (Stage 4 or M). Moreover, a rare metastatic form of sponta-
neously regressing/maturating disease (Stage 4S or MS) may occur
in children below the age of 18 months (2–5). Over the years,
major efforts have been focused to unveil the genetic and biologi-
cal features of the different forms of NB in order to identify novel
prognostic factors and druggable targets. To date, stage, patient’s
age, and presence or absence of the amplification of MYCN, a
transcription factor crucial for central nervous system (CNS)
development (6), are considered major predictors of patients’
clinical outcome. Moreover, risk-group stratification is based upon
additional parameters such as loss of chromosome 11q, tumor
histology, and ploidy (3, 5). MYCN amplification strongly asso-
ciates with loss of heterozygosity at chromosome 1p and occurs in
approximately 15% of children affected by NB, with increased fre-
quency in stage 4 patients (approximately 50%). A more accurate
evaluation of the risk of treatment failure according to these prog-
nostic factors allowed overtime a significant reduction of mortality
in patients that at diagnosis presented with localized non-MYCN-
amplified tumors (low-risk) and non-MYCN-amplified stage 4
under 18 months of age (intermediated-risk), who received less
aggressive surgical and chemotherapeutic treatments. In particu-
lar, Rubie and coworkers have recently demonstrated that low-dose
chemotherapy improved 5 years survival of 9% in infants with low-
risk NB without threatening symptoms compared to cases treated
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with high dose chemotherapy due to resistance to the low-dose
regimen or presence of one threatening symptom (7). A more
dramatic scenario exists in children with high-risk NB at diag-
nosis, which includes stage 4 patients <18 months with MYCN
amplification or >18 months with or without MYCN amplifi-
cation and rare patients with MYCN-amplified localized tumors
(3, 5). These patients have a 5-year survival rate <50% although
receiving aggressive combination therapies that include intensive
chemotherapy, surgery, radiotherapy, autologous stem cell trans-
plantation, and the administration of Retinoids (13-cis-retinoic
acid) (3, 5), which represent adjuvants for high-risk NB ther-
apy (8) due to their capability of driving neuronal differentiation
in vitro (9).
Over the years, several studies focused on the identification of
new molecular targets. However, although different experimental
approaches have been used, including whole-genome sequencing,
few somatic mutations in druggable pathways have been iden-
tified. Mutations in the anaplastic lymphoma receptor tyrosine
kinase (ALK ) are infrequent (<10% of sporadic NB). Mutations in
the a-thalassemia/mental retardation syndrome X-linked (ATRX)
gene are most common. However, they have not been identified
in MYCN-amplified NB and the ATRX molecule does not appear
to drive tumorigenesis (10, 11). Recurrent genetic alterations that,
however, require further investigations, have been reported in the
RAC–RHO pathway and in chromatin-remodeling genes At-rich
interactive domain 1A (ARID1A) and 1B (ARID1B) (11–13). Due
to the difficulty at targeting directly the MYCN transcription fac-
tor, the major oncogenic driver identified so far (14), new strategies
currently aim to neutralize molecules involved in apoptosis, angio-
genesis, invasion, or metastasis (5). Interestingly, the antibody-
mediated targeting of the oncofetal differentiation antigen GD2 in
combination with GM-CSF and IL-2 resulted in an improved out-
come of patients and has been recently included in the standard
care of high-risk NB (15). Unfortunately, pain, the major side effect
of this therapy (16), as well as cytokine release syndrome and irido-
plegia, limits its use; moreover, to date, only patients with minimal
residual disease can benefit of this therapeutic approach (17). The
success of the anti-GD2/GM-CSF/IL-2 therapy might depend on
the FcγR-mediated activation of granulocytes (18) as well of other
immune cell types such as macrophages and natural killer (NK)
lymphocytes.
Among cytotoxic lymphocytes, NK cells represent the most
potent anti-tumor effectors and represent promising weapons
against aggressive tumors such as NB (19, 20). In addition, as
recently demonstrated, they may also attack cancer stem cells
(CSC), i.e. tumor cells with stem cell properties (21–23). Thus,
in the past decade, several studies have been focused on the identi-
fication of the molecular mechanisms involved in the interaction
between NB and NK cells in order to establish a convincing biolog-
ical starting point for a novel NK cell-based immunotherapeutic
approach.
NATURAL KILLER CELLS AND NEUROBLASTOMA
RECOGNITION
Tumor cells express surface molecules that either switch off
or switch on NK cell-mediated cytotoxicity. HLA class I
molecules on tumors negatively regulate NK cell function
by engaging immunoreceptor tyrosine-based inhibition motifs
(ITIM)-bearing receptors (24) that include the inhibitory killer
Ig-like receptors (KIRs, CD158), highly polymorphic clonally dis-
tributed receptors able to distinguish among different HLA-A,
-B, and -C allotypes (25), and CD94/NKG2A heterodimers, spe-
cific for non-classical HLA-E (26). KIR and CD94/NKG2A are
differently expressed in CD56bright CD16− and CD56dull CD16+
NK cell subsets, which represent sequential stages of maturation
(27, 28). While high numbers of CD56bright CD16−, KIR−, IFN-
γ producing cells are found in non-reactive lymph nodes and
tumor sites, the majority of NK cells circulating in the blood are
mature CD56dull CD16+, KIR+, cytolytic (perforinhigh) cells (29).
CD56bright can progress to CD56dull cells, which upon activation
increase the cytotoxic and IFN-γ producing capabilities (28, 30).
Tumor cells switch on NK cell function by expressing at the
cell surface non-MHC class I, “danger” molecules that are recog-
nized by an array of activating NK receptors. These include both
the FcγRIII (CD16) that mediates the antibody-dependent cyto-
toxicity (ADCC) and receptors that function in the absence of
antibodies. These latter molecules mainly consist of the NKp46,
NKp30, and NKp44 receptors, collectively termed natural cyto-
toxicity receptors (NCR), which are mostly NK-restricted, and
NKG2D and DNAM-1 that are also expressed by T cell subsets
(31). In the last decade, several groups dedicated many efforts to
unveil the nature of the surface tumor ligands specifically recog-
nized by the activating receptors. NKp46 still remains a receptor
with “orphan ligand,” while NKp44 has been shown to recognize
a novel isoform of the mixed-lineage leukemia (MLL5) protein
(32) and NKp30 binds to B7-H6 molecules (33). The NKG2D and
DNAM-1 (CD226) receptors recognize MICA/B and ULBPs or,
PVR (CD155) and Nectin-2 (CD112), respectively (31). DNAM-
1 shares the capability of recognizing PVR with tactile (CD96)
(34) and TIGIT (35). All the ligands identified so far represent de
novo expressed danger signals or molecules that are expressed in
healthy cells and over-expressed upon tumor transformation. In
most cases, the expression on tumors of multiple ligands leads to
the engagement of different activating NK receptors that cooperate
in triggering the anti-tumor cytotoxicity (31).
When both inhibitory and activating receptors are engaged by
the specific ligands on potential targets, the function of ITIM-
bearing inhibitory receptors dominates over activation. Thus, in
an autologous setting NK lymphocytes spare healthy cells that
express high, “protective” levels of HLA class I molecules while
they kill tumors, such as NB, in which HLA class I expression is
downregulated (36, 37). Moreover, NK cells kill allogeneic targets
that express non-self MHC class I alleles. This might occur when
two individuals are “KIR/KIR-ligand mismatched,” i.e., individual
A is characterized by fully functional, educated NK cell subset(s)
expressing KIR specific for HLA class I alleles that are missing in
individual B. In the context of HLA-haploidentical hematopoi-
etic stem cell transplantation (haplo-HSCT), the presence of a
KIR/KIR-ligand mismatch in the donor versus recipient direc-
tion allows donor’s NK cell subsets to kill recipient’s (HLA class
Ihigh) residual leukemic blasts thus resulting into a graft-versus-
leukemia effect (GvL), as well as mature DC and activated T
lymphocytes, thus preventing graft-versus-host-disease (GvHD)
and graft-rejection, respectively (38).
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In NB, initial data were obtained by the use, as target cells, of
in vitro established NB cell lines (39). NK cells displayed strong
cytolytic activity against different NB cells and NCR were involved
in the mechanisms leading to killing (39). The susceptibility of
human NB cell lines to NK-mediated killing was validated in
the context of a metastatic model set up in NOD/SCID mice.
In this experimental setting, repeated infusions of IL-2 or IL-15
activated NK cells resulted in both an increased mean survival
time of HTLA-230-bearing mice and reduced BM infiltration (40).
Considering that long term cultured cell lines might be poorly rep-
resentative of original tumors, more interesting data originated
from in vitro studies that use neuroblasts, freshly purified from
BM aspirate of stage 4 patients (36) (Figures 1 and 2). In this
study, allogeneic activated NK cells killed neuroblasts isolated from
patients although at a lesser extent as compared to the NB cell lines
used as control. According to the absence or negligible expression
of HLA class I molecules, the NK-mediated lysis of neuroblasts
did not increase in the presence of anti-HLA class I mAb. Dif-
ferent molecular mechanisms responsible for the reduced HLA
class I expression in NB cells have been elucidated. The immuno-
histochemical analysis of high-risk human NB showed different
abnormalities in the antigen processing machinery, which include
defects in the expression of immunoproteasomal subunits LMP2
and LMP7 and of transporters of antigen processing (TAP) (37).
In vitro treatment of NB cells with IFN-γ induced up-regulation
of HLA class I expression (37). Although decreasing their sus-
ceptibility to autologous NK cells, this up-regulation of HLA
class I molecules could enhance T cell-mediated recognition. In
this context, a restoration of killing mediated by antigen specific
(MAGE3) cytolytic T cells was observed upon cotransfection of NB
cell lines with IRF1 and NF-kB p65, HLA class I transcriptional
activators that are also induced by INFγ and TNFα, respectively
(41). It cannot be excluded that also in vivo neuroblasts could
acquire/upregulate HLA class I expression. For example, this might
occur in the context of transplantation or following the anti-GD2
antibody-mediated therapy that engages FcγR+ immune cells such
as NK cells, which are capable of releasing high amounts of IFN-γ
upon activation (Figure 1). This phenomenon was observed in
a murine NB model, where recurrent tumors developed after an
NK-dependent anti-tumor response induced by a humanized IL-2
immunocytokine targeted to GD2. In these mice, NB cells showed
markedly enhanced MHC class I expression as compared with
tumors growing in controls (42). The possible in vivo increase of
HLA class I expression in NB cells could explain the benefit of a
KIR/KIR-L mismatch in the NK versus NB direction (43–45).
Bone marrow-purified neuroblasts from different patients,
although expressing in all instances low levels of HLA class I, dis-
played a great heterogeneity in terms of susceptibility to lysis by
NK cells. The good or poor susceptibility to NK-mediated killing
correlated with the presence or the absence of PVR expression
on neuroblasts (Figures 1 and 2A)(36). Interestingly, neuroblasts
lacking PVR expression were from patients in relapse, whereas
those expressing PVR were from children at the onset of the dis-
ease, suggesting a possible correlation between PVR expression and
NB status. The predominant role of DNAM-1/PVR interaction in
NK-mediated killing is striking considering that, in most cases,
killing of human tumors depends on the cooperation between
FIGURE 1 | Inhibitory and activating interactions between human NK
cells and neuroblasts. NB express ligands that are recognized by NK
receptors with activating or inhibitory function. While DNAM-1/PVR
interactions play a pivotal role in triggering NK cell-mediated killing, B7-H3
dampens NK cell function. NB usually lack or express low, non-protective
levels of HLA class I molecules. However, therapeutic approaches such as
the in vivo administration of anti-GD2 Abs could induce not only ADCC of
NB but also the release of INF-γ, which upregulates the expression of the
ligands for inhibitory KIR.
various activating receptors (31). In this context, it is of note that
none of the BM-purified neuroblast fractions expressed major
adhesion molecules such as ICAM1 or LFA-3 (36). Thus, in NB
the presence of PVR, originally described as an adhesion molecule,
could become critical in rendering tumor cells susceptible to NK-
mediated killing. Although PVR and nectin-2 are closely related
molecules of the Nectin family, the presence/absence of nectin-2
on NB cells did not influence the susceptibility to NK-mediated
killing. Nectin-2, which displays binding affinity to DNAM-1 sim-
ilar to PVR (46), also shows homophilic recognition. This, by
hampering its recognition by DNAM-1, may force the receptor
to preferentially bind PVR (46). In line with the increased killing
of PVR+ neuroblasts, mAb mediated masking of DNAM-1 signif-
icantly reduced the NK-mediated lysis of neuroblasts showing a
pivotal role of DNAM-1 in NB cell killing. While a minor con-
tribution of NKp46 and NKp30 activating receptors could be
appreciated (36), consistent with the low expression of the spe-
cific ligands, NKG2D did not play a significant role in killing of
BM-purified neuroblasts (Figure 1). The expression of NKG2D
ligands has been also investigated in human primary NB and cell
lines (47). MICA, MICB, and ULBPs transcripts were found in
most tumors and cell lines. However, MICA surface expression was
absent in primary tumors and present only in some NB cell lines.
Importantly, the soluble form of MICA (sMICA) was detected in
sera of most patients and in the culture supernatant of some cell
lines and was shown to downregulate NKG2D surface expression
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FIGURE 2 | NB-mediated mechanisms of escape from the NK-mediated immunosurveillance. (A) Downregulation of PVR, ligand of DNAM-1 activating
receptor, renders NB cells poorly susceptible to NK-mediated killing. (B) NB can release soluble MICA, exosome-associated B7-H3, immunomodulatory factors
such as MIF and TGF-β1. TGF-β1 might be also released by tumor-associated macrophages (TAM) that display M2-like functional properties.
in peripheral-blood T cells and decrease NK cell-mediated killing
of MICA+ NB cells (47) (Figure 2B). MICB was detected exclu-
sively in the cytosol of NB cells, either primary tumors or cell lines.
ULBP-1 was rarely detected, ULBP-2 was expressed by approxi-
mately 50% of primary tumors and cell lines, and ULBP-3 was
absent in primary tumors but was expressed in most NB cell
lines (47).
A crucial role of the DNAM-1 receptor has also been reported
in myeloid and lymphoblastic leukemia (48), ovarian tumors (49),
and different murine tumor models (50, 51). In particular, it has
been shown that in response to chemical carcinogens, DNAM-
1-deficient mice develop more DNAM-1 ligand+ fibrosarcoma
and papilloma cells than wt mice. Thus, the study of the mol-
ecular mechanisms responsible for the modulation of DNAM-1
ligands appears to be highly relevant. In this context, it has been
shown that malignant RAJI lymphoma cells present hypermethy-
lated PVR promoter-associated CpG islands. The epigenetic status
was partially reversed by hypomethylating agents that led to upreg-
ulation of both transcription and surface expression of PVR (52).
PVR up-regulation has been shown to be dependent on DNA-
damage response (DDR)-dependent pathways that are activated
by oxidative stress (53). Moreover, modulation of PVR surface
expression might occur during infections. Different pathogen-
derived stimuli such as LPS, poly I:C, and flagellin upregulated the
surface expression of PVR (and nectin-2) in human DC (54) and
in murine antigen-presenting cells (55) via the MYD88 and TRIF
pathways. It has also been shown that expression of the human
immunodeficiency virus type 1 (HIV-1)Vpr protein increases PVR
levels in Jurkat T cells. This is due to activation of ATR kinase that
triggers the DDR pathway and G2 arrest. Moreover, Vpr induces
a PVR upregulation in HIV-infected CD4+ T lymphocytes that
overcomes the PVR downregulation induced by the HIV Nef pro-
tein (56). A negative regulation of PVR surface expression has
been observed during cytomegalovirus (CMV) infection resulting
in ineffective NK cell-mediated killing of infected cells (57). The
UL141 viral glycoprotein is responsible for PVR downregulation,
since it retains the immature form of PVR in the endoplasmic retic-
ulum (57). Recently, it has been shown that UL141 binds to PVR
with high affinity (58). Considering the role of PVR in determin-
ing high susceptibility to the NK-mediated attack, up-regulation
of PVR surface expression might represent an appealing strategy
to strengthen the immune responses against tumors. However, the
dark side of PVR function cannot be disregarded. Indeed, although
data in NB are missing, PVR has been described as a positive
regulator of cancer progression, since it is capable of enhancing
tumor cell invasiveness and migration (59). Thus, further studies
are required to understand whether the immunological favorable
effects of PVR up-regulation might balance the induction of a
more aggressive tumor phenotype.
A tumor-promoting role has been shown also for B7-H3, a
surface molecule originally identified on NB thanks to the gener-
ation of a specific monoclonal antibody (M5B14) (60). Studies
on different tumor histotype indicate that B7-H3 might drive
tumor cell development by different molecular mechanisms. These
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include the capability of B7-H3 of reducing the effect of the
chemotherapeutic-induced apoptosis in breast (61) and pancre-
atic carcinoma (62), as well as that of promoting migration and
invasiveness (63, 64). The latter properties have been confirmed
in vivo in an orthotopic model that showed that xenografted
B7-H3 silenced glioma cells invaded significantly less into the
surrounding brain tissue as compared to wt tumors. Moreover,
B7-H3 expressed on glioblastoma cells negatively regulated NK
cell-mediated cytotoxicity (64). These observations are consis-
tent with previous data demonstrating that B7-H3 expression on
BM-purified neuroblasts decreased NK cell-mediated killing (60)
(Figure 1). Thus, different experimental approaches demonstrated
that, in humans, B7-H3 might block the NK-mediated attack by
interacting with a still unknown inhibitory NK receptor. A sol-
uble form of B7-H3 (sB7-H3) that results from MMPs cleavage
of the surface protein was detected in sera of tumor patients and
appeared to correlate with tumor burden (65, 66). Moreover, B7-
H3 is present in NB cell lines-derived exosomes (67). The exosome-
associated form could inhibit NK cell function by engaging the
B7-H3-specific inhibitory receptor (Figure 2B). Thus, B7-H3 is
an interesting NB-associated molecule that combines immune-
evading and tumor progression properties. This correlates with
the negative prognostic value associated to high expression of B7-
H3 in several tumor types (64, 66, 68–72). In particular, in primary
NB (73), high B7-H3 surface intensity and percentage of positive
cells correlated with poor event-free survival. Interestingly, the dif-
ferences in event-free survival were observed also in patients with
localized disease (stage 1–3), suggesting the need of a more care-
ful follow-up/aggressive treatment of B7-H3+ low-risk patients. It
should be mentioned that, in the mouse system, B7-H3 has been
described as a “friend” in tumor immunology (74). In particular,
intratumoral injection of an expression plasmid encoding mouse
B7-H3 led to complete regression of 50% of tumors, which was
mediated by NK and CD8+ T cells (75). It is to note that the mouse
B7-H3 gene codes for a molecule characterized by two Ig-like
domains (2Ig-B7-H3) in the order IgV and IgC, while the predom-
inant isoform in human tissues and cell lines is a longer molecule
(4Ig-B7-H3) characterized by four Ig-like domains (IgV–IgC–IgV–
IgC), which results from duplication of the exons encoding the IgV
and IgC domains (76). The mouse B7-H3 has been shown to bind
the TREM-like transcript 2 (TREML2, TLT-2) triggering receptor,
which is expressed by myeloid cells, CD8+ T cells, and activated
CD4+ T cells (77, 78). In humans, TREML2 does not appear to
be a receptor of B7-H3 (79) and the predominant inhibitory role
of B7-H3 strongly suggests the existence of a (still undefined)
receptor that down-regulates NK cell function. However, the exis-
tence in the human system of specific receptors with opposite
functions cannot be excluded. Indeed, human B7-H3 belongs to
the B7 family that includes members such as B7–1 (CD80), B7–2
(CD86), B7-H2 (ICOS-L), B7-H1 (PD-L1), B7-DC (PD-L2), B7-
H4 (B7S1, B7x), and BT3 (80), some of which represent specific
ligands of receptors with either activating or inhibitory function.
The scenario should become even more complex when consider-
ing that the B7-H3 inhibitory and activating receptors might be
co-expressed in immune cells rather than expressed in different
cell types/subsets.
TUMOR ESCAPE MECHANISMS IN NEUROBLASTOMA AND
POSSIBLE NOVEL NK CELL-BASED IMMUNOTHERAPEUTIC
APPROACHES
In principle, downregulation of HLA class I surface expression
allows NB to evade T cell-mediated attack operated by the host
immune system (36, 37), while rendering tumor cells susceptible
to NK cell-mediated recognition and killing (31). However, both
the fast tumor progression in high-risk NB patients and the in vitro
data highlighted the existence of additional escape mechanisms
that dampen the NK cell-mediated anti-tumor activity as well. As
discussed above, the lack of ligands for activating receptors such
as PVR (36) (Figure 2A), MICA/ULBPs (36, 37), or adhesion mol-
ecules (36, 81) represents a strategy allowing NB cells to strongly
reduce their susceptibility to NK-mediated killing. Thus, one could
set up immunotherapeutic interventions aimed at upregulating
the expression of these ligands. However, the role of PVR in tumor
progression (59), as well as its expression in normal cells, should
not be underestimated. In particular, DNAM-1 co-operates with
NKp30 or NKp46 in the NK-mediated killing of autologous imma-
ture DC and unpolarized (M0) or M2-polarized macrophages,
which express low, “non-protective” amounts of HLA class I mol-
ecules. Conversely, mature DC and M1-polarized macrophages
express high levels of HLA class I molecules and are protected
by the NK cell-mediated attack (54, 82). The NK-mediated selec-
tion of DC and macrophages with optimal antigen-presentation
properties has been named “immunoediting” and results from the
fine-tuning of inhibitory and activating signals provided by the
ligands physiologically expressed by DC and macrophages. The
forced over-expression of ligands for activating receptors, such as
PVR, might dangerously alter the immunoediting process. More-
over, it should be taken into account that PVR is expressed in
normal endothelium, where it plays a role in leukocyte extravasa-
tion (83, 84). Also in this case, up-regulation of PVR expression
might overcome the HLA class I-mediated inhibitory signals and
result in loss of self-tolerance toward autologous endothelium.
On the other hand, it has been shown in primary glioblastoma
that endothelial cells of proliferating tumor vessels express PVR at
higher surface densities as compared to normal vessels (22). More-
over, several studied indicated that most tumor cells including
CSC constitutively express levels of PVR higher than the normal
counterparts (21). Although further studies are needed to dis-
sect the possible side effects, therapeutic approaches focused on
PVR might represent a chance in the treatment of highly aggres-
sive tumors such as NB. Up-regulation of PVR in NB patients
might increase the susceptibility to NK-mediated lysis of PVR+
NB and restored that of PVR− NB. In this context, it is of note that
the lack of PVR expression was detected in given BM metastatic
neuroblasts (36) while no data are available on PVR expression
in primary tumors. Thus, it cannot be excluded that PVR− NB
cells might originate because of the selection pressure occurring
during the dissemination process and that primary tumors could
contain PVR+ targetable neuroblasts. If so, a larger cohort of
patients might benefit from PVR up-regulation therapies. Impor-
tantly, PVR might represent a powerful therapeutic target on both
neuroblasts and NB-associated vessels. PVR has been originally
identified as the receptor for the poliovirus, a highly contagious
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virus that only affects humans. As already mentioned in a study
performed in a poliovirus-susceptible animal model, the oncolytic
treatment by a novel attenuated poliovirus eradicated PVR+ NB
cells without signs of paralysis (85).
B7-H3 might represent an additional attractive molecular tar-
get in NB. Beside its tumor-promoting properties, human B7-H3
represents a shield protecting HLA class I low/− neuroblasts from
the NK cell-mediated attack (60,64) (Figure 1). B7-H3 is expressed
in normal endothelium, but is strongly upregulated in tumor-
associated vasculature (86). Encouraging results derived from the
first in-human intrathecal injection of radioiodinated anti-B7-H3
Ab (following surgery, craniospinal irradiation, and chemother-
apy) in 21 NB patients with recurrent CNS metastasis (87). Sev-
enteen patients remained CNS disease free and had a median
survival time (33 months) significantly better than patients treated
with standard protocols (6.6 months) (88). Anti-B7-H3 antibod-
ies, possibly delivered using lipid-based (liposome) formulations
(89–91), might represent a suitable option to target tumoricidal
compounds to NB and to increase immune responses (Figure 3).
Indeed,acting on different cell types, it might simultaneously block
invasiveness/migration of tumor cells, destroy tumor-associated
vessels, and strength the activity of NK cells. Moreover, anti-B7-
H3 antibodies might induce NK cell-mediated ADCC against NB
and destroy the B7-H3/inhibitory receptor interactions. An alter-
native approach to trigger NK cell function might consist in the
use of bi-specific antibodies reacting with B7-H3 (on tumor cells)
and activating receptors (on NK cells). In addition B7-H3 might
be considered as a molecule alternative to GD2 in CAR-based
immunotherapy (Figure 3). CAR are chimeric antigen receptors,
formed by tumor-specific Ab single chain Fv fragments (scFvs)
genetically fused through a transmembrane domain to the CD3ζ
chain, which are transfected into cytolytic lymphocytes (92, 93).
The use of CD19-specific CARs resulted in a significant clinical
benefit in two children with B-cell precursor acute lymphoblas-
tic leukemia (94). The NK92 cell line engineered to express the
GD2-specific CAR showed increased cytolytic activity against NB
cell lines and primary NB cells (95). Moreover, T lymphocytes
equipped with GD2-specific CAR are being used in preclinical
and phase I studies with clinical benefit in NB patients (96, 97).
Essential requirement in CAR-based immunotherapy is the selec-
tion of an adequate tumor surface antigen with a documented
tumor-promoting role (92). B7-H3 satisfies this criterion, thus
representing a suitable candidate in CAR-based immunotherapy.
Moreover, while GD2-specific CAR target a molecule that is eas-
ily shed by the NB cell surface (98), B7-H3-specific CAR would
target a stable type I transmembrane surface molecule expressed
by NB cells and NB-associated vessels. Infusion of engineered
and/or activated (by cytokine or DC) (99) NK cells might be
helpful in adoptive immunotherapeutic approaches of high-risk
NB patients receiving autologous (5) or haplo-HSCT. Indeed, a
gap of several weeks exists between the infusion of CD34+ stem
cells and the appearance in peripheral blood of fully “armed”
mature NK cells (38). During the early post-transplant period,
lack of NK-mediated immunosurveillance could favor re-growth
of residual NB cells escaping the preparative regimen to the allo-
graft, this causing tumor relapses. Haplo-HSCT, which represents
a new standard therapy in the cure of adult and pediatric leukemic
FIGURE 3 | Possible immunotherapeutic approaches that target B7-H3
and trigger NK cell function. (A) Anti-B7-H3 antibodies induce ADCC of
NK cells against NB. (B) Bi-specific antibodies that react with B7-H3 on NB
and trigger activating receptors on NK cells. (C) NK cells engineered with
B7-H3-specific CAR that transduce activating signals via CD3 chain.
patients, could also increase the event-free survival of NB patients
(45). Recently, a novel transplant strategy based on negative deple-
tion of both α/β T lymphocytes and of CD19+ B-cells has been
proposed for pediatric hematological disorders. This approach
leaves in the graft an array of immune cells with anti-tumor prop-
erties, including mature armed donor-derived alloreactive NK cells
and γ/δ T cells (38). Also in this type of transplant that pre-
serves donor mature NK cells in the graft, engineered NK cells
might support the anti-tumor responses. In the perspective of
in vivo NK-based adoptive immunotherapies as adjuvant in dif-
ferent transplant strategies, recent studies optimized the in vitro
expansion and activation of NK cells that preserved the anti-NB
activity (100–103).
In addition to the escape mechanisms described above (47, 60,
104), NB cells produce soluble factors such as MIF (105, 106)
and TGF-β (107) capable of dampening NK cell activity (108,
109) (Figure 2B). Initial data showed that in vitro conditioning
of NK cells with rTGF-β1 resulted in downregulation of NKp30
and NKG2D activating receptors and in significant reduction of
NK-mediated killing (109). Different studies confirmed in vivo
the role of TGF-β in regulating NKG2D expression and function
in NK cells (110, 111). Although knockout mice lacking TGF-β1 or
TGF-β2 showed distinct phenotypes suggesting that each isoform
could also have specific, non-overlapping functions (112), in vitro
high concentrations of both rTGF-β1 and rTGF-β2 (>10 ng/ml)
showed similar capability of inhibiting the expression of the acti-
vating NK receptors (113). It has been shown that NB cell lines
released low/medium amounts of TGF-β1 (<3 ng/ml), which were
unable to significantly downregulate NKp30 and NKG2D expres-
sion while clearly modulated the chemokine receptor repertoire
of NK cells (113). Interestingly, non-MYCN-amplified NB cells
produced amounts of TGF-β1 (and several other soluble factors)
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significantly higher than MYCN amplified cells (113). NB-derived
TGF-β1 upregulated the expression of CXCR4 and CXCR3 in all
NK cells and downregulated that of CX3CR1 in the CD56dim
subset. Notably, a similar altered chemokine receptor repertoire
was observed in peripheral-blood NK cells of stage 4 NB patients
resulting in the appearance of a CX3CR1low CD56dim NK cell
population. In patients, also a tendency to CXCR3 upregulation
on CD56bright NK cells was appreciated. No significant differ-
ences in CXCR4 expression were detected in NK cells from NB
patients as compared to healthy donors. This might be due to a
general difficulty in detecting in vivo CXCR4 expression, which
in particular in the BM, might be fully occupied by the CXCL12
(SDF1) ligand (114). In NK cells from NB patients, also a sig-
nificant CXCR1 down-modulation was observed, that, however,
was TGF-β1-independent (113). Thus, in vivo, NB cells can release
TGF-β1 and other, still unknown soluble factor(s) that profoundly
affect the expression of a number of chemokine receptors that
play pivotal roles in NK cell BM homing, egress, interaction with
endothelium, and recruitment into peripheral tissues. High con-
centrations of TGF-β1 might locally exert a paracrine effect on
tumor-associated NK cells that might decrease their anti-tumor
activity by downregulating NKp30 and NKG2D expression. In
this context, it has been shown that CD56bright, immature, poor
cytolytic NK cells represent the major subset present in tumor
tissues (115, 116). The above data suggest that TGF-β1 antag-
onists and/or proinflammatory cytokines capable of overcoming
the modulatory effect of TGF-βmight represent a reasonable adju-
vant therapy in the cure of different tumors, including NB. In this
context, mouse models showed that use of IL-2 targeted to GD2 is
associated with increased infiltration of NK (and CD8+ T cells)
in subcutaneous NB (117).
Novel immunotherapeutic approaches should also consider
the complexity of tumor microenvironment that is populated
by different immune cell types that could be endowed with
immunomodulatory functions. These cells include fibroblasts
(118), regulatory T cells (Treg), myeloid derived suppressor cells
(MDSC) (119), and tumor-associated macrophages (TAM) (120).
Different NB mouse models demonstrated the immunosuppres-
sive and tumor-promoting role of Treg (120) and MDSC (121).
To date, however, data on their presence within the human NB
tumor and on their clinical relevance are still scarce. A recent
study showed that metastatic NB have higher infiltration of TAM
than locoregional tumors, and that metastatic tumors in patients
≥18 months have higher expression of inflammation-related genes
than those in patients <18 months (122). TAM are characterized
by an“M2-like”functional phenotype and exert tumor-promoting
and immunoregulatory properties, including the release of TGF-
β1 (120) (Figure 2). M2-polarized macrophages still present a
functional plasticity and they can be recommitted toward an
M1-like tumor suppressing, immunostimulatory phenotype. In
particular, it has been shown that microbial products such as
LPS or BCG reverted their functional phenotype toward M1,
which released immunostimulatory cytokines (IL-12, IL-18) and
induced strong activation of autologous NK cells. NK cells up-
regulated CD69 and CD25 (that associates with CD122 to form
the high-affinity receptor for IL-2), expressed CCR7 (a chemokine
receptor involved in homing of NK cells to secondary lymphoid
organs), increased the anti-tumor cytolytic activity, and released
high amounts of IFN-γ (82). Interestingly, it has been shown
that a subset (30–40%) of M2 express a membrane-bound form
of IL-18 (mIL-18) that is released upon TLR stimulation (123,
124). This soluble form of IL-18 (sIL-18) by acting in close cell-
to-cell contact is crucial for both IFN-γ release and expression
of CCR7 by NK cells. These data suggest that reconverting the
immunosuppressive TAM phenotype using apathogenic TLR lig-
ands might represent an additional immunotherapeutic approach
to fully activate immature tumor-associated NK cells.
CONCLUSION
Progress in the understanding of NB cell biology will allow a more
accurate stratification of patients, thus reducing toxic side effects
of aggressive therapy in low-risk patients. High-risk patients who
currently have a dismal prognosis could benefit from multidis-
ciplinary therapeutic protocols that include novel NK cell-based
immunotherapeutic strategies. The latter will take advantage of
our knowledge about the presence/absence of NB-associated lig-
ands interacting with activating/inhibitory receptors expressed by
NK cells. Moreover, it should also take into account the mul-
tiple immunomodulatory strategies set up by NB and various
immune cell types to impair the recruitment and activation of
NK cells in the tumor microenvironment. The encouraging results
emerged from haploidentical hematopoietic cell transplantation in
pediatric hematological malignancies, might strongly motivate a
re-evaluation of transplant approaches in the therapy of high-risk
NB patients.
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